Impax Laboratories, Inc. (IPXL) Reaches $19.17 After 3.00% Down Move; Last Week PennantPark Investment (PNNT) Coverage

April 25, 2018 - By Darrin Black

Impax Laboratories, Inc. (NASDAQ:IPXL) Logo

Among 12 analysts covering Pennant Investment (NASDAQ:PNNT), 5 have Buy rating, 0 Sell and 7 Hold. Therefore 42% are positive. Pennant Investment had 34 analyst reports since August 6, 2015 according to SRatingsIntel. On Wednesday, August 9 the stock rating was upgraded by JP Morgan to “Overweight”. The rating was upgraded by J.P. Morgan to “Buy” on Wednesday, August 9. The firm has “Hold” rating by Keefe Bruyette & Woods given on Thursday, February 8. The stock of PennantPark Investment Corporation (NASDAQ:PNNT) earned “Hold” rating by Jefferies on Friday, September 22. The stock of PennantPark Investment Corporation (NASDAQ:PNNT) earned “Hold” rating by Jefferies on Tuesday, August 15. The rating was upgraded by Ladenburg Thalmann on Friday, February 9 to “Buy”. On Wednesday, November 23 the stock rating was downgraded by FBR Capital to “Mkt Perform”. Keefe Bruyette & Woods maintained it with “Hold” rating and $8.5000 target in Monday, July 24 report. Keefe Bruyette & Woods maintained PennantPark Investment Corporation (NASDAQ:PNNT) rating on Friday, June 23. Keefe Bruyette & Woods has “Hold” rating and $8.5000 target. The rating was maintained by MLV on Thursday, August 6 with “Buy”. See PennantPark Investment Corporation (NASDAQ:PNNT) latest ratings:

09/02/2018 Broker: Ladenburg Thalmann Old Rating: Neutral New Rating: Buy Upgrade
08/02/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $7.5 Maintain
19/01/2018 Broker: Jefferies Rating: Hold New Target: $7.0 Maintain
03/11/2017 Broker: Jefferies Rating: Hold New Target: $8.0 Maintain
26/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $8.5 Maintain

The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) is a huge mover today! The stock decreased 3.40% or $0.68 during the last trading session, reaching $19.17. About 254,561 shares traded. Impax Laboratories, Inc. (NASDAQ:IPXL) has risen 51.97% since April 25, 2017 and is uptrending. It has outperformed by 40.42% the S&P500.The move comes after 9 months negative chart setup for the $1.38 billion company. It was reported on Apr, 25 by Barchart.com. We have $18.59 PT which if reached, will make NASDAQ:IPXL worth $41.31 million less.

Investors sentiment increased to 1.18 in Q4 2017. Its up 0.20, from 0.98 in 2017Q3. It improved, as 12 investors sold PennantPark Investment Corporation shares while 28 reduced holdings. 16 funds opened positions while 31 raised stakes. 26.98 million shares or 0.25% less from 27.05 million shares in 2017Q3 were reported. Stephens Inc Ar owns 15,143 shares. Burgundy Asset Mgmt Limited, Ontario – Canada-based fund reported 2.34M shares. Moreover, Stifel Financial Corp has 0% invested in PennantPark Investment Corporation (NASDAQ:PNNT). Ares Mgmt Limited Liability Corporation has 856,394 shares for 0.19% of their portfolio. Blackrock Incorporated reported 453,436 shares. Arrowmark Colorado Holding Ltd Liability Co stated it has 1.62 million shares or 0.11% of all its holdings. Citadel Advsrs Llc holds 73,858 shares or 0% of its portfolio. The California-based Aperio Gp Limited Liability Corporation has invested 0% in PennantPark Investment Corporation (NASDAQ:PNNT). 30,869 are owned by Eagle Limited Com. Pinebridge Limited Partnership holds 0.01% or 41,885 shares in its portfolio. The Massachusetts-based Wellington Group Llp has invested 0% in PennantPark Investment Corporation (NASDAQ:PNNT). Wells Fargo & Co Mn reported 410,798 shares or 0% of all its holdings. Private Advisor has invested 0.01% in PennantPark Investment Corporation (NASDAQ:PNNT). Jpmorgan Chase And holds 2.08 million shares or 0% of its portfolio. Janney Montgomery Scott Lc holds 198,699 shares.

The stock decreased 0.78% or $0.05 during the last trading session, reaching $6.79. About 74,696 shares traded. PennantPark Investment Corporation (NASDAQ:PNNT) has declined 13.46% since April 25, 2017 and is downtrending. It has underperformed by 25.01% the S&P500.

PennantPark Investment Corporation specializes in direct and mezzanine investments in middle market companies. The company has market cap of $482.28 million. It invests in the form of mezzanine debt, senior secured loans, and equity investments. It has a 7.82 P/E ratio. The fund typically invests in building and real estate, hotels and gaming, electronics, healthcare, education and childcare, financial services, printing and publishing, consumer products, business services, energy and utilities, distribution, gas and oil, media, environmental services, aerospace and defense, manufacturing industries and retail.

Analysts await Impax Laboratories, Inc. (NASDAQ:IPXL) to report earnings on May, 9. They expect $0.17 EPS, up 54.55% or $0.06 from last year’s $0.11 per share. IPXL’s profit will be $12.21M for 28.19 P/E if the $0.17 EPS becomes a reality. After $0.11 actual EPS reported by Impax Laboratories, Inc. for the previous quarter, Wall Street now forecasts 54.55% EPS growth.

Among 22 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Impax Laboratories Inc. had 52 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) earned “Hold” rating by Guggenheim on Tuesday, December 12. The rating was maintained by UBS with “Sell” on Monday, October 30. The firm earned “Buy” rating on Wednesday, August 9 by Cantor Fitzgerald. WallachBeth Capital downgraded Impax Laboratories, Inc. (NASDAQ:IPXL) on Monday, November 14 to “Hold” rating. The firm has “Hold” rating given on Wednesday, September 13 by Canaccord Genuity. The firm has “Hold” rating given on Friday, March 2 by RBC Capital Markets. Susquehanna initiated Impax Laboratories, Inc. (NASDAQ:IPXL) on Tuesday, July 21 with “Positive” rating. The rating was upgraded by Goldman Sachs on Tuesday, September 27 to “Neutral”. The company was initiated on Monday, June 6 by Goldman Sachs. The rating was maintained by RBC Capital Markets with “Hold” on Tuesday, October 17.

Investors sentiment decreased to 1.26 in Q4 2017. Its down 0.49, from 1.75 in 2017Q3. It dropped, as 27 investors sold Impax Laboratories, Inc. shares while 45 reduced holdings. 36 funds opened positions while 55 raised stakes. 73.13 million shares or 11.06% more from 65.84 million shares in 2017Q3 were reported. Regions Corp owns 3,130 shares for 0% of their portfolio. Ubs Asset Americas has 0% invested in Impax Laboratories, Inc. (NASDAQ:IPXL). Hanseatic Mgmt Svcs reported 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). Commonwealth Of Pennsylvania School Empls Retrmt System, Pennsylvania-based fund reported 143,289 shares. Alps Advisors has invested 0.01% in Impax Laboratories, Inc. (NASDAQ:IPXL). Advisory Ntwk Limited Com owns 0% invested in Impax Laboratories, Inc. (NASDAQ:IPXL) for 90 shares. Parametric Associates Ltd Llc invested in 0% or 262,176 shares. New York-based Capstone Inv Advsrs Limited Liability Com has invested 0.01% in Impax Laboratories, Inc. (NASDAQ:IPXL). Moreover, Ny State Teachers Retirement has 0% invested in Impax Laboratories, Inc. (NASDAQ:IPXL). Public Employees Retirement Of Ohio stated it has 6,307 shares or 0% of all its holdings. Sg Americas Ltd Limited Liability Company reported 0.01% stake. Menta Lc reported 60,385 shares. Switzerland-based Credit Suisse Ag has invested 0.03% in Impax Laboratories, Inc. (NASDAQ:IPXL). Tci Wealth Advsrs owns 59 shares for 0% of their portfolio. Renaissance Lc stated it has 0.02% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL).

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.38 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

PennantPark Investment Corporation (NASDAQ:PNNT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: